IL312045A - טיפול בשילוב מעכבי o-glcnacase (oga). - Google Patents
טיפול בשילוב מעכבי o-glcnacase (oga).Info
- Publication number
- IL312045A IL312045A IL312045A IL31204524A IL312045A IL 312045 A IL312045 A IL 312045A IL 312045 A IL312045 A IL 312045A IL 31204524 A IL31204524 A IL 31204524A IL 312045 A IL312045 A IL 312045A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- given
- amino acid
- acid sequence
- n3pg
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 68
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 claims 62
- 208000024827 Alzheimer disease Diseases 0.000 claims 26
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 206010012289 Dementia Diseases 0.000 claims 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 8
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 8
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- OFNRINRWEARWEM-CABZTGNLSA-N N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical group FC=1N=C(SC=1CN1[C@H](C[C@H](CC1)OCC=1OC(=NN=1)C)C)NC(C)=O OFNRINRWEARWEM-CABZTGNLSA-N 0.000 claims 4
- 206010044688 Trisomy 21 Diseases 0.000 claims 4
- 230000001594 aberrant effect Effects 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 4
- 230000002776 aggregation Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000001228 spectrum Methods 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- FRVXHWNHGWUTQO-CABZTGNLSA-N N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical group FC=1N=C(SC=1CN1[C@H](C[C@H](CC1)OCC1=NOC(=N1)C)C)NC(C)=O FRVXHWNHGWUTQO-CABZTGNLSA-N 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270820P | 2021-10-22 | 2021-10-22 | |
| PCT/US2022/078475 WO2023070064A1 (en) | 2021-10-22 | 2022-10-21 | O-glcnacase (oga) inhibitor combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312045A true IL312045A (he) | 2024-06-01 |
Family
ID=84362190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312045A IL312045A (he) | 2021-10-22 | 2022-10-21 | טיפול בשילוב מעכבי o-glcnacase (oga). |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4419551A1 (he) |
| KR (1) | KR20240099297A (he) |
| CN (1) | CN118139880A (he) |
| AU (1) | AU2022371475A1 (he) |
| CA (1) | CA3235104A1 (he) |
| IL (1) | IL312045A (he) |
| MX (1) | MX2024004514A (he) |
| WO (1) | WO2023070064A1 (he) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| BR112013004056B8 (pt) | 2010-08-12 | 2022-10-18 | Lilly Co Eli | Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende |
| DK2970272T3 (en) | 2013-03-14 | 2019-04-23 | Merck Patent Gmbh | glycosidase |
| DE102016106204A1 (de) | 2016-04-05 | 2017-10-05 | Airbus Operations Gmbh | Aufnahmesystem zur Aufnahme von Personen und Gegenständen für eine Kabine eines Fahrzeugs sowie ein damit ausgestattetes Flugzeug |
| EP3496750A2 (en) * | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| AR111693A1 (es) * | 2017-05-25 | 2019-08-07 | Lilly Co Eli | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga |
| JP2021530552A (ja) * | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
| EP3977135A1 (en) | 2019-05-31 | 2022-04-06 | Eli Lilly And Company | Compounds and methods targeting human tau |
-
2022
- 2022-10-21 KR KR1020247016365A patent/KR20240099297A/ko unknown
- 2022-10-21 IL IL312045A patent/IL312045A/he unknown
- 2022-10-21 EP EP22813018.3A patent/EP4419551A1/en active Pending
- 2022-10-21 CN CN202280070979.2A patent/CN118139880A/zh active Pending
- 2022-10-21 WO PCT/US2022/078475 patent/WO2023070064A1/en active Application Filing
- 2022-10-21 MX MX2024004514A patent/MX2024004514A/es unknown
- 2022-10-21 AU AU2022371475A patent/AU2022371475A1/en active Pending
- 2022-10-21 CA CA3235104A patent/CA3235104A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024004514A (es) | 2024-05-07 |
| AU2022371475A1 (en) | 2024-05-09 |
| WO2023070064A1 (en) | 2023-04-27 |
| KR20240099297A (ko) | 2024-06-28 |
| CN118139880A (zh) | 2024-06-04 |
| CA3235104A1 (en) | 2023-04-27 |
| EP4419551A1 (en) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192233T1 (hr) | Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba | |
| CN110167960B (zh) | 针对金黄色葡萄球菌溶血素a毒素的人类抗体 | |
| JP2013542194A5 (he) | ||
| RU2013138711A (ru) | Антитела против фактора роста эндотелия сосудов (vegf) | |
| JP2020141669A5 (he) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| JP2015514110A5 (he) | ||
| JP7165588B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| JP2020504142A5 (he) | ||
| RU2020126237A (ru) | Гуманизированные тау-антитела при болезни альцгеймера | |
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| RU2511410C3 (ru) | АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2017536102A5 (he) | ||
| JP2015535828A5 (he) | ||
| RU2014136332A (ru) | Композиции и способы применения ингибиторов csf1r | |
| RU2008120625A (ru) | НОВОЕ ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ИЛ-1β | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| JP2012523417A5 (he) | ||
| RU2016127812A (ru) | Способы введения антагонистов интегрина бета7 | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| JP2010520276A5 (he) | ||
| IL312045A (he) | טיפול בשילוב מעכבי o-glcnacase (oga). | |
| JP2018515532A5 (he) | ||
| RU2015102068A (ru) | Антитела к теофиллину и способы их применения | |
| TW201827055A (zh) | 組合療法 |